|Bid||247.55 x 1200|
|Ask||250.00 x 1000|
|Day's Range||247.99 - 253.35|
|52 Week Range||198.64 - 258.45|
|Beta (5Y Monthly)||0.58|
|PE Ratio (TTM)||25.60|
|Earnings Date||Apr 25, 2022 - Apr 29, 2022|
|Forward Dividend & Yield||7.76 (3.14%)|
|Ex-Dividend Date||May 16, 2022|
|1y Target Est||251.76|
The U.S. Senate Finance Committee is widening its investigation into the tax practices of U.S. drugmakers to include Amgen Inc, according to a letter sent on Thursday by the committee's chairman, Senator Ron Wyden. Amgen is already in the crosshairs of the U.S. Internal Revenue Service over its tax practices, particularly how it allocates profits between the U.S. and Puerto Rico. The IRS is after more than $10 billion in back taxes and penalties the California-based biotech firm, although Amgen has said it believes the proposed adjustments and penalties are without merit.
Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.
A small study of Amgen Inc's Lumakras drug combined with immunotherapy found it helped 29% of advanced lung cancer patients, but liver toxicity was high and further study is needed, the company said ahead of the data presentation on Sunday at the World Conference on Lung Cancer in Vienna. Nearly all of the 58 trial patients treated with the highest dose of genetic-mutation targeting Lumakras experienced elevated liver enzyme levels, and about 20% given the lowest dose saw significant liver toxicity, researchers said.